NCT03419702 is a NA clinical trial of Almonds in PreDiabetes, sponsored by Maastricht University Medical Center.

Who is sponsoring NCT03419702?

NCT03419702 is sponsored by Maastricht University Medical Center.

What drugs are being tested in NCT03419702?

Interventions in NCT03419702: Almonds.

What condition does NCT03419702 study?

NCT03419702 studies PreDiabetes, Impaired Glucose Tolerance, Impaired Fasting Glucose, Overweight and Obesity.

Is NCT03419702 still recruiting?

NCT03419702 is currently completed. Last updated 4 March 2022.

Last reviewed 2022-03-04 · How we verify

NCT03419702

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Almonds and Health Effects on Metabolism, Vascular Function and Cognition

Completed NA Last updated 4 March 2022

What this trial tests

NA trial testing Almonds in PreDiabetes in 43 participants. Completed in 3 December 2021.

Timeline

10 January 2018

Primary endpoint
3 December 2021

3 December 2021

Quick facts

Lead sponsor	Maastricht University Medical Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	supportive care
Enrollment	43
Start date	10 January 2018
Primary completion	3 December 2021
Estimated completion	3 December 2021
Sites	1 location across Netherlands

Drugs / interventions tested

Almonds

Conditions studied

PreDiabetes — all drugs for PreDiabetes →
Impaired Glucose Tolerance — all drugs for Impaired Glucose Tolerance →
Impaired Fasting Glucose — all drugs for Impaired Fasting Glucose →
Overweight and Obesity — all drugs for Overweight and Obesity →

Sponsor

Maastricht University Medical Center

Who can join

Adults 40 to 70, any sex, with PreDiabetes or Impaired Glucose Tolerance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of the proposed study is to examine and understand the impact of long-term almond consumption on chronic glucose metabolism in subjects with impaired glucose tolerance and/or impaired fasting glucose.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The effects of long-term almond consumption on whole-body insulin sensitivity, postprandial glucose responses, and 48 h continuous glucose concentrations in males and females with prediabetes: a randomized controlled trial.
Gravesteijn E, Mensink RP, Plat J. · · 2023 · cited 10× · PMID 37258943 · DOI 10.1007/s00394-023-03178-w
Effects of long-term almond consumption on markers for vascular function and cardiometabolic risk in men and women with prediabetes: results of a randomized, controlled cross-over trial.
Chavez-Alfaro MA, Mensink RP, Gravesteijn E, Joris PJ, et al · · 2024 · cited 3× · PMID 39546040 · DOI 10.1007/s00394-024-03510-y

Verify or expand the search:

Other trials of Almonds

Trials testing the same drug.

NCT05782218 — Healthy Unique Lipids From Almonds · NA · completed
NCT04958018 — Almond Supplementation and Exercise Recovery · NA · completed
NCT04778371 — The Effects of Almond Consumption on Functional Performance and Activity in Overweight Active Older Adults · NA · active not recruiting
NCT04223323 — Effects of Almond Consumption on the Human Gastrointestinal Microbiota and Metabolic Health · NA · completed
NCT04243395 — Protein Source on Plasma Amino Acid Concentrations In Older Adults · NA · completed

Other recruiting trials for PreDiabetes

Currently open trials in the same condition.

NCT06897982 — Feasibility of a Nutrition Intervention for Patients With Prediabetes at a Federally Qualified Health Center · NA · recruiting
NCT06967558 — The Role of Islet GLP-1 in the Pathogenesis of Prediabetes · Phase 2 · recruiting
NCT06482944 — Whole Food for Families: A Pilot RCT of a Dietary Guidelines-Based Intervention to Prevent Type 2 Diabetes · NA · recruiting
NCT06989164 — Post Prandial Individual Responses to Different Foods · NA · recruiting
NCT07254572 — Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes · Phase 4 · recruiting

Other Maastricht University Medical Center trials

Trials by the same sponsor.

NCT04603261 — Time to Excretion of Contrast, a Maastricht Prospective Observational Study · withdrawn
NCT04598516 — Maastricht Investigation of Renal Function in Absence of- and Post- Contrast in Patients With eGFR LEss Than 30 · withdrawn
NCT04597892 — Efficacy of Point-Of-Care Creatinine Assays in Patients With eGFR <30 Receiving Intravascular Contrast · withdrawn
NCT07287358 — Optimal Cerebral Perfusion Pressure Guided Therapy: Assessment of Target Effectiveness - II · NA · not yet recruiting
NCT07501780 — Real-world Evaluation of the Implementation of LC-OCT in Daily Clinical Practice · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03419702 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Maastricht University Medical Center
Last refreshed: 4 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03419702.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing